
    
      The study is a Phase II, single-arm, open-label, single-dose clinical trial, and its primary
      objective is to evaluate the efficacy and safety of CNCT19 Cell Injection in the treatment of
      relapsed or refractory NHL. The study consists of screening period (8 weeks), treatment
      period (4 weeks), and follow-up period (2 years at most).
    
  